CYTODYN INC. FORM OF STOCK OPTION AWARD AGREEMENT (FOR NON-EMPLOYEE DIRECTORS)Stock Option Award Agreement • August 29th, 2013 • Cytodyn Inc • Pharmaceutical preparations • Oregon
This STOCK OPTION AWARD AGREEMENT (this “Option Agreement”) is made effective as of , 201_, by and between CytoDyn Inc., a Colorado corporation (the “Corporation”), and (the “Participant”).
THIS STOCK OPTION AND THE COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR APPLICABLE STATE SECURITIES LAWS. NEITHER THIS STOCK OPTION NOR THE COMMON STOCK ISSUABLE UPON EXERCISE HEREOF MAY BE...Stock Option Agreement • August 29th, 2013 • Cytodyn Inc • Pharmaceutical preparations • Oregon
This STOCK OPTION AWARD AGREEMENT (this “Option Agreement”) is made , 201 , by and between CytoDyn Inc., a Colorado corporation (the “Company”), and (the “Grantee”).
FORM OF COMMON STOCK WARRANT AGREEMENTCommon Stock Warrant Agreement • August 29th, 2013 • Cytodyn Inc • Pharmaceutical preparations • California
This is to certify that, for value received, Jordan Naydenov, or a proper assignee (in case, the “Holder”), is entitled to purchase, subject to the provisions of this Warrant A, from CytoDyn, Inc (“CytoDyn”), at any time after 180 days from the date of the execution of the (Promissory Note) (the “Commencement Date”) to 5:00 p.m., California time, on the next business day five (5) years form the Commencement Date, (the “Expiration Date”) at which time this Warrant A shall expire and become void, one (1) share for each $1.00 invested, (“Warrant A Shares”) of Common Stock (the “Common Stock”) of CytoDyn, Inc., a Colorado corporation (the “Company”). This Warrant A shall be exercisable at One Dollar ($1.00) per share (the “Exercise Price”). The number of shares of Common Stock to be received upon exercise of this Warrant A and the Exercise price shall be adjusted from time to time as set forth below. This Warrant A also is subject to the following terms and conditions:
EMPLOYMENT AND NON-COMPETE AGREEMENTEmployment Agreement • August 29th, 2013 • Cytodyn Inc • Pharmaceutical preparations • Florida
THIS EMPLOYMENT AND NON-COMPETE AGREEMENT (this “Agreement”) dated October 17, 2011 and is effective as of August 1, 2011 (the “Effective Date”), between Nader Pourhassan (“Employee”) and CytoDyn Inc., a Colorado corporation (the “Company”). The Company and Employee are hereinafter sometimes referred to collectively as the “Parties” or individually as a “Party.”
DEVELOPMENT AND LICENSE AGREEMENT between PROTEIN DESIGN LABS, INC. and PROGENICS PHARMACEUTICALS, INC.Development and License Agreement • August 29th, 2013 • Cytodyn Inc • Pharmaceutical preparations • California
This Agreement (“Agreement”), effective as of April 30, 1999 (“Effective Date”), is made by and between PROTEIN DESIGN LABS, INC., a Delaware corporation having offices at 34801 Campus Drive, Fremont, CA 94555 (hereinafter “PDL”), and PROGENICS PHARMACEUTICALS, INC., a Delaware corporation having offices at 777 Old Saw Mill River Road, Tarrytown, NY 10591 (hereinafter “PROGENICS”).
CONSULTING AGREEMENTConsulting Agreement • August 29th, 2013 • Cytodyn Inc • Pharmaceutical preparations • Oregon
This Consulting Agreement (this “Agreement”) is made and entered into effective March 28, 2013 (the “Effective Date”), by and between CytoDyn Inc. (the “Company”), and Michael Nobel, an individual (“Consultant”).
THIS STOCK OPTION AND THE COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR APPLICABLE STATE SECURITIES LAWS. NEITHER THIS STOCK OPTION NOR THE COMMON STOCK ISSUABLE UPON EXERCISE HEREOF MAY BE...Stock Option Agreement • August 29th, 2013 • Cytodyn Inc • Pharmaceutical preparations • Oregon
This STOCK OPTION AWARD AGREEMENT (this “Option Agreement”) is made effective as of , 201 , by and between CytoDyn Inc., a Colorado corporation (the “Company”), and (the “Grantee”).
CLINICAL RESEARCH COLLABORATION AGREEMENTClinical Research Collaboration Agreement • August 29th, 2013 • Cytodyn Inc • Pharmaceutical preparations • Pennsylvania
This Clinical Research Collaboration Agreement, effective on the last date of signature (“Effective Date”), is by and between CytoDyn, Inc., a Colorado, Corporation principally located at Lake Oswego, Oregon, (“Company”) and Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine, a 501(c)(3) Pennsylvania, nonprofit corporation principally located at 245 N. 15th Street, Philadelphia, PA 19102 (“Institution”). Company and Institution shall herein be individually referred to as “Party” and collectively referred to as “Parties.”
